The drug has faced widespread criticism since its FDA approval, but the July 11 calls specifically target CMS to issue a national coverage determination to prevent access disparities.
The statement also urged CMS to pair the move with coverage with evidence development, which would track efficacy and safety.
Insurers have also challenged Aduhelm, with Point32Health threatening not to cover the drug due to its hefty price tag.
Eyes are on CMS for next steps, as Medicare will likely pay the majority of the price tag for the drug, but access could be restricted due to the cost.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
